A Study of Zanubrutinib in Patients With ITP

计划入组 20 人 · 首次发布于 2022 年 3 月 15 日

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

计划入组 50 人 · 首次发布于 2022 年 12 月 8 日

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

计划入组 30 人 · 首次发布于 2022 年 8 月 10 日

Acalabrutinib(Calquence)

C₂₆H₂₃N₇O₂ · Rx

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Bruton's tyrosine kinase inhibitor(TargetRx)

Inhibikase Therapeutics

United States

Exelixis, Inc.

United States

Regeneron Pharmaceuticals

United States

Ibrutinib Shows Promise in Treating Chronic Graft-Versus-Host Disease

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Acanthamoeba Encephalitis in Chronic Lymphocytic Leukemia: Case Report Highlights Infection Risk with Ibrutinib